GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EOM Pharmaceutical Holdings Inc (OTCPK:IMUC) » Definitions » Cyclically Adjusted Price-to-FCF

EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) Cyclically Adjusted Price-to-FCF : (As of May. 22, 2024)


View and export this data going back to 2006. Start your Free Trial

What is EOM Pharmaceutical Holdings Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


EOM Pharmaceutical Holdings Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for EOM Pharmaceutical Holdings's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EOM Pharmaceutical Holdings Cyclically Adjusted Price-to-FCF Chart

EOM Pharmaceutical Holdings Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

EOM Pharmaceutical Holdings Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of EOM Pharmaceutical Holdings's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, EOM Pharmaceutical Holdings's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EOM Pharmaceutical Holdings's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EOM Pharmaceutical Holdings's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where EOM Pharmaceutical Holdings's Cyclically Adjusted Price-to-FCF falls into.



EOM Pharmaceutical Holdings Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

EOM Pharmaceutical Holdings's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2018 is calculated as:

For example, EOM Pharmaceutical Holdings's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2018 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jun. 2018 (Change)*Current CPI (Jun. 2018)
=-0.519/106.3168*106.3168
=-0.519

Current CPI (Jun. 2018) = 106.3168.

EOM Pharmaceutical Holdings Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200809 -14.156 92.307 -16.305
200812 -13.281 88.697 -15.919
200903 -16.438 89.744 -19.474
200906 -24.188 91.003 -28.258
200909 -15.757 91.120 -18.385
200912 -7.243 91.111 -8.452
201003 -18.297 91.821 -21.186
201006 -23.625 91.962 -27.313
201009 -28.321 92.162 -32.671
201012 -17.426 92.474 -20.035
201103 -25.787 94.283 -29.078
201106 -17.958 95.235 -20.048
201109 -21.619 95.727 -24.011
201112 -25.056 95.213 -27.978
201203 -38.967 96.783 -42.806
201206 -33.110 96.819 -36.358
201209 -22.752 97.633 -24.776
201212 -25.742 96.871 -28.252
201303 -17.109 98.209 -18.521
201306 -14.477 98.518 -15.623
201309 -14.036 98.790 -15.105
201312 -19.112 98.326 -20.665
201403 -18.181 99.695 -19.389
201406 -18.514 100.560 -19.574
201409 -16.691 100.428 -17.670
201412 -13.433 99.070 -14.416
201503 -15.646 99.621 -16.698
201506 -17.097 100.684 -18.054
201509 -28.668 100.392 -30.360
201512 -25.735 99.792 -27.418
201603 -23.487 100.470 -24.854
201606 -25.185 101.688 -26.331
201609 -16.267 101.861 -16.979
201612 -10.538 101.863 -10.999
201703 -17.099 102.862 -17.673
201706 -9.727 103.349 -10.006
201709 -1.450 104.136 -1.480
201712 -1.176 104.011 -1.202
201803 -0.382 105.290 -0.386
201806 -0.519 106.317 -0.519

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


EOM Pharmaceutical Holdings  (OTCPK:IMUC) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


EOM Pharmaceutical Holdings Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of EOM Pharmaceutical Holdings's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) Business Description

Traded in Other Exchanges
N/A
Address
136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645
EOM Pharmaceutical Holdings Inc is focused on developing novel immunomodulatory and retinal disease drug agents to address a range of inflammatory, viral, retinal, and other diseases. Its product candidate includes dual-acting broad-spectrum immunomodulator EOM613, which has the potential to treat cancer cachexia and rheumatoid arthritis, and its advanced formulation of EOM147 is being studied to treat serious retinal diseases without the need for intraocular injection.
Executives
Andrew Gengos director 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Gary Titus director, officer: Chairman and Secretary SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Mark A Schlossberg director C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Rahul Singhvi director 246 HOLLY DRIVE, CHALFONT PA 18914
Helen Susan Kim director 3832 BAY CENTER PLACE, HAYWARD CA 94545
Richard Chin director C/O OXIGENE, INC., 230 THIRD AVENUE, WALTHAM MA 02451
Richard Cowell director 7840 VIRGINIA OAK DRIVE, GAINSVILLE VA 20155
James G. Bender officer: VP, Product Development & Mfg. 112 WEST 34TH STREET, 17TH FLOOR, NEW YORK NY 10120
Manish Singh director, officer: President & CEO 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Jacqueline Brandwynne director 649 STONE CANYON ROAD, LOS ANGELES CA 90077

EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) Headlines